The 16S Ribosomal RNA pipeline drugs market research report outlays comprehensive information on the 16S Ribosomal RNA targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 16S Ribosomal RNA pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, Dermatology, Respiratory, and Genito Urinary System which include the indications Gram-Negative Bacterial Infections, Pseudomonas aeruginosa Infections, Acne Vulgaris, Rosacea, Cystic Fibrosis, Bronchiectasis, Urinary Tract Infections, and Pyelonephritis. It also reviews key players involved in 16S Ribosomal RNA targeted therapeutics development with respective active and dormant or discontinued products.
The 16S Ribosomal RNA pipeline targets constitutes close to 26 molecules. Out of which, approximately 24 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 3, 2, 2, 2, 3, 8, and 4 respectively. Similarly, the universities portfolio in Phase III, and Discovery comprises 1, and 1 molecule.
16S Ribosomal RNA overview
16S ribosomal RNA (16S rRNA) is a component of the 30S subunit of a prokaryotic ribosome. It is found in all bacteria and archaea. It is required for the initiation of protein synthesis and the stabilization of correct codon-anticodon pairing in the A site of the ribosome during mRNA translation.
For a complete picture of 16S Ribosomal RNA’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
